Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
54-92-2
Molecular formula
C9H13N3O
Molecular weight
179.22 g/mol
Drug class
Hydrazine-derived monoamine oxidase inhibitor (MAOI)historical antidepressant and antitubercular agent
Mechanism of action
Irreversibly inhibits monoamine oxidase, reducing breakdown of serotonin, noradrenaline and dopamine and increasing monoaminergic neurotransmission. The same non-selective MAO inhibition contributes to clinically significant interactions and toxicity.
Indications / reported uses
Historically introduced for treatment of depressive illness and originally used as an antitubercular agent. It is no longer a routine contemporary antidepressant because of serious hepatotoxicity and other safety concerns; this entry is historical pharmacology, not a current treatment recommendation.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Iproniazid Environmental Risk Assessment (ERA) (the Iproniazid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.